Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy
Author(s) -
Halle C. F. Moore,
Joseph M. Unger,
KellyAnne Phillips,
Frances Boyle,
Erika Hitre,
David Porter,
Prudence A. Francis,
Lori J. Goldstein,
Henry Gómez,
Carlos Vallejos,
Ann H. Partridge,
Shaker R. Dakhil,
Agustin A. García,
Julie R. Gralow,
Janine Lombard,
John Forbes,
Silvana Martino,
William E. Barlow,
Carol J. Fabian,
Lori M. Minasian,
Frank L. Meyskens,
Richard D. Gelber,
Gabriel N. Hortobágyi,
Kathy S. Albain
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1413204
Subject(s) - medicine , goserelin , oncology , adjuvant , breast cancer , chemotherapy , ovarian cancer , adjuvant chemotherapy , gynecology , cancer
Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom